Research Forum 2023
29 - 31 May 2023
Gold Coast, Queensland, Australia
Discovery, Diagnostics and Management:
A new era for Dementia
OPPORTUNITY TO PARTNER WITH US
Our sponsors and exhibitors are an integral and essential component of our discipline. The ADRF 2023 will be providing a unique opportunity for all those involved in the dementia network of prevention, treatment and care to come together to share knowledge, engage and connect. Your involvement will allow optimum exposure for your company and products.
To find out more about the packages available, please download the prospectus below or contact:
Rates of Dementia Expected to Reach 1M by 2058
In Australia, the number of persons with dementia is expected to reach 1 million by 2058, but the good news is that research discoveries are accelerating with new treatments for Alzheimer’s disease and accurate diagnostic blood tests, now emerging.
From 29 - 31 May 2023, the world’s top dementia researchers, health professionals and policymakers, along with people living with dementia and their families and carers, will gather at the Marriott Gold Coast Resort & Spa, Queensland for the annual Australian Dementia Research Forum (ADRF 2023).
Dementia Australia is the source of trusted information, education and services for the estimated half a million Australians living with dementia, and the almost 1.6 million people involved in their care.
We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible.
Founded by carers more than 35 years ago, today we are the national peak body for people living with dementia, their families and carers. We involve people impacted by dementia and their experiences in our activities and decision-making, to make sure we are representative of the diverse range of dementia experiences. We amplify the voices of people impacted by dementia through advocating and sharing stories to help inform and inspire others.
No matter how you are impacted by dementia or who you are, we are here for you.
Networking Reception Sponsor
Actinogen is conducting Phase 2 trials in people with early-stage Alzheimer’s Disease and cognitive impairment associated with Depression. Xanamem®, is a promising oral therapy with positive clinical data from three placebo-controlled trials.
For more information visit www.actinogen.com.au
® Xanamem is a registered trademark of Actinogen Medical Limited
THANK YOU TO OUR SPONSORS
10 January 2023
10 February 2023
29 May 2023
29-31 May 2023